Improving treatment effectiveness for advanced prostate cancer
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
This study is looking at how to make a special cancer treatment work better for men with advanced prostate cancer by understanding the genes and immune responses of their tumors, so they can improve results and help prevent the cancer from coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10886513 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of prostate-specific membrane antigen-targeted radiopharmaceutical therapy (PSMA-RPT) for patients with metastatic castration-resistant prostate cancer (mCRPC). The team aims to understand the genetic and molecular factors that influence how tumors respond to this therapy. By conducting detailed studies on tumor samples and exploring the immune response, they hope to identify ways to improve patient outcomes and reduce the chances of relapse after treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who are undergoing or considering PSMA-RPT.
Not a fit: Patients with early-stage prostate cancer or those not eligible for PSMA-RPT may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in enhancing cancer therapies through similar genetic and immunological approaches, indicating potential for success in this area.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Czernin, Johannes — University of California Los Angeles
- Study coordinator: Czernin, Johannes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.